[
    {
        "pregunta": "1. What is the recommended frequency for screening proteinuria in people with SLE without known kidney disease?",
        "respuesta": "For people with systemic lupus erythematosus (SLE) without known kidney disease, it is generally recommended to screen for proteinuria at least annually. More frequent screening may be warranted based on disease activity or other risk factors."
    },
    {
        "pregunta": "2. What is the role of hydroxychloroquine (HCQ) in the management of lupus nephritis?",
        "respuesta": "Hydroxychloroquine (HCQ) plays an important role in the management of lupus nephritis as an adjunctive therapy. It helps reduce disease activity, decreases flares, and may improve long-term renal outcomes by modulating the immune response. HCQ also has a steroid-sparing effect and is associated with reduced thrombosis risk and improved survival in systemic lupus erythematosus (SLE) patients. It is generally recommended as part of the standard treatment regimen for lupus nephritis unless contraindicated."
    },
    {
        "pregunta": "3. When is preemptive kidney transplantation recommended over dialysis in lupus nephritis patients nearing end-stage kidney disease (ESKD)?",
        "respuesta": "Preemptive kidney transplantation is recommended over dialysis in lupus nephritis patients nearing end-stage kidney disease (ESKD) when the patient has stable lupus disease activity, no active systemic inflammation, and is considered suitable for transplantation. Early transplantation, before starting dialysis, is preferred to improve long-term outcomes, reduce complications associated with dialysis, and enhance quality of life. Careful assessment of disease remission and overall health is essential to ensure optimal timing for transplantation."
    },
    {
        "pregunta": "4. Describe the components of triple therapy for lupus nephritis.",
        "respuesta": "Triple therapy for lupus nephritis typically includes the following components:\n\n1. **Corticosteroids** – to rapidly reduce inflammation and suppress the immune response.\n2. **Mycophenolate mofetil (MMF) or Cyclophosphamide** – as immunosuppressive agents to control disease activity and prevent kidney damage.\n3. **Calcineurin inhibitors (e.g., tacrolimus or cyclosporine)** – to further suppress immune activity and improve kidney outcomes.\n\nThis combination aims to maximize efficacy by targeting different immune pathways while minimizing toxicity."
    },
    {
        "pregunta": "5. How should glucocorticoid dosing be managed over the course of lupus nephritis treatment?",
        "respuesta": "Glucocorticoid dosing in lupus nephritis is typically initiated with a high dose to rapidly control inflammation, often using oral prednisone (e.g., 0.5–1 mg/kg/day) or intravenous methylprednisolone pulses for severe cases. After achieving disease control, the dose is gradually tapered to the lowest effective maintenance dose to minimize long-term side effects. The tapering schedule depends on clinical response, renal function, and side effects, often over several months. Throughout treatment, glucocorticoids are usually combined with immunosuppressive agents to improve efficacy and allow for lower steroid doses."
    },
    {
        "pregunta": "6. How should refractory lupus nephritis be managed after failure of two standard therapy courses?",
        "respuesta": "Refractory lupus nephritis after failure of two standard therapy courses should be managed by considering alternative immunosuppressive agents such as rituximab or calcineurin inhibitors (e.g., tacrolimus or cyclosporine). Participation in clinical trials may be appropriate. Close monitoring and supportive care, including blood pressure control and renin-angiotensin system blockade, are essential. In some cases, combination therapy or escalation to agents like mycophenolate mofetil or cyclophosphamide (if not previously used or maximized) may be considered. Consultation with a lupus nephritis specialist is recommended."
    },
    {
        "pregunta": "7. What considerations are important when managing lupus nephritis in older adults?",
        "respuesta": "When managing lupus nephritis in older adults, important considerations include:\n\n1. **Comorbidities:** Older patients often have multiple health issues (e.g., hypertension, diabetes, cardiovascular disease) that can affect treatment choices and outcomes.\n\n2. **Medication Tolerance:** Increased sensitivity to immunosuppressive drugs and higher risk of adverse effects such as infections, cytopenias, and drug toxicity.\n\n3. **Renal Function:** Age-related decline in kidney function may complicate dosing and increase risk of nephrotoxicity.\n\n4. **Polypharmacy:** Potential drug interactions due to multiple medications.\n\n5. **Disease Presentation:** Lupus may present differently or be less active, requiring individualized treatment intensity.\n\n6. **Monitoring:** Closer monitoring for side effects and disease progression is essential.\n\n7. **Functional Status and Frailty:** Assessing overall health and frailty to balance treatment benefits and risks.\n\nTailoring therapy to minimize toxicity while effectively controlling disease activity is key in this population."
    },
    {
        "pregunta": "8. What are the recommendations for managing lupus nephritis in children with childhood-onset SLE?",
        "respuesta": "Management of lupus nephritis in children with childhood-onset systemic lupus erythematosus (SLE) typically involves a combination of immunosuppressive therapy and supportive care:\n\n1. **Induction Therapy:** High-dose corticosteroids combined with immunosuppressive agents such as intravenous cyclophosphamide or mycophenolate mofetil (MMF) to control active inflammation.\n\n2. **Maintenance Therapy:** After induction, lower doses of corticosteroids along with immunosuppressants like MMF or azathioprine are used to maintain remission and prevent relapse.\n\n3. **Supportive Care:** Control of hypertension, proteinuria (using ACE inhibitors or ARBs), and management of complications such as infections or anemia.\n\n4. **Monitoring:** Regular assessment of renal function, urine analysis, and serological markers to evaluate disease activity and treatment response.\n\n5. **Multidisciplinary Approach:** Involving pediatric rheumatologists, nephrologists, and other specialists as needed.\n\nThese recommendations are generally adapted from adult protocols but tailored to the pediatric population considering growth, development, and long-term side effects. Early diagnosis and aggressive treatment improve renal outcomes in children with lupus nephritis."
    },
    {
        "pregunta": "9. Why is shared decision-making emphasized in the treatment of lupus nephritis, and what factors should be discussed with patients?",
        "respuesta": "Shared decision-making is emphasized in the treatment of lupus nephritis because the condition and its therapies can significantly impact patients’ quality of life, involve complex risk-benefit considerations, and require long-term management. Engaging patients helps ensure that treatment aligns with their values, preferences, and lifestyle, improving adherence and outcomes.\n\nFactors to discuss with patients include:\n- The severity and prognosis of their kidney involvement\n- Potential benefits and risks of treatment options (e.g., immunosuppressive drugs, corticosteroids)\n- Possible side effects and monitoring requirements\n- Impact on fertility, pregnancy, and comorbid conditions\n- Lifestyle modifications and supportive care measures\n- Patient goals, concerns, and preferences regarding treatment intensity and quality of life"
    },
    {
        "pregunta": "10. What is the recommended initial glucocorticoid regimen for active lupus nephritis?",
        "respuesta": "The recommended initial glucocorticoid regimen for active lupus nephritis typically involves high-dose oral prednisone (e.g., 0.5–1 mg/kg/day) or intravenous methylprednisolone pulses (e.g., 500–1000 mg daily for 3 days) followed by a gradual taper. This is usually combined with immunosuppressive therapy such as mycophenolate mofetil or cyclophosphamide. The exact regimen may vary based on disease severity and clinical guidelines."
    },
    {
        "pregunta": "11. How should medication dosage be adjusted in lupus nephritis patients with decreased glomerular filtration rate (GFR)?",
        "respuesta": "In lupus nephritis patients with decreased glomerular filtration rate (GFR), medication dosages—especially for renally cleared drugs such as immunosuppressants (e.g., cyclophosphamide, mycophenolate mofetil) and certain adjunctive medications—should be adjusted to avoid toxicity. This typically involves reducing the dose or extending the dosing interval based on the degree of renal impairment. Regular monitoring of kidney function and drug levels (when applicable) is essential to guide safe and effective dosing. Always consult specific drug guidelines for renal dosing adjustments."
    },
    {
        "pregunta": "12. When should a kidney biopsy be performed in a patient with SLE?",
        "respuesta": "A kidney biopsy should be performed in a patient with systemic lupus erythematosus (SLE) when there is evidence of lupus nephritis, such as persistent proteinuria (usually >0.5 g/day), active urinary sediment (e.g., hematuria, cellular casts), or impaired renal function. The biopsy helps classify the type and severity of lupus nephritis, guiding treatment decisions."
    },
    {
        "pregunta": "13. What adjunctive therapies should be considered in lupus nephritis to improve overall kidney health?",
        "respuesta": "Adjunctive therapies in lupus nephritis to improve overall kidney health include blood pressure control (preferably with ACE inhibitors or ARBs), lipid management (statins), use of hydroxychloroquine, lifestyle modifications (such as smoking cessation, diet, and exercise), and prevention of infections and osteoporosis. These measures help reduce proteinuria, control comorbidities, and protect kidney function alongside immunosuppressive treatment."
    },
    {
        "pregunta": "14. When is the addition of renin-angiotensin-aldosterone system inhibitors (RAAS-I) recommended in lupus nephritis?",
        "respuesta": "The addition of renin-angiotensin-aldosterone system inhibitors (RAAS-I) in lupus nephritis is recommended primarily to reduce proteinuria and control hypertension. RAAS-I are typically introduced once immunosuppressive therapy has been initiated, especially in patients with persistent proteinuria (>0.5 g/day) and/or hypertension, to provide renal protection and help preserve kidney function."
    },
    {
        "pregunta": "15. What immunosuppressive agents are preferred in the treatment of lupus nephritis, and why?",
        "respuesta": "The preferred immunosuppressive agents for the treatment of lupus nephritis are **mycophenolate mofetil (MMF)** and **cyclophosphamide**. \n\n**Reasons:**\n\n- **Mycophenolate mofetil (MMF):** It is favored due to its efficacy in inducing and maintaining remission, a better side effect profile, and lower risk of infertility compared to cyclophosphamide.\n- **Cyclophosphamide:** Often used in more severe or proliferative lupus nephritis cases, it is effective but has more significant toxicity, including risks of infection, hemorrhagic cystitis, and infertility.\n- Both agents are typically used in combination with corticosteroids to reduce inflammation and immune activity.\n\nCurrent guidelines recommend MMF as the first-line agent for induction and maintenance therapy, especially in non-Asian populations, whereas cyclophosphamide may be preferred in certain severe cases or specific ethnic groups."
    },
    {
        "pregunta": "16. What are the indications for repeat kidney biopsy in patients with lupus nephritis (LN)?",
        "respuesta": "Indications for repeat kidney biopsy in patients with lupus nephritis (LN) include:\n\n1. **Clinical relapse or worsening renal function:** When there is a flare of LN manifested by increased proteinuria, hematuria, or rising serum creatinine after a period of remission.\n2. **Unclear or atypical clinical course:** To differentiate between active inflammation amenable to immunosuppression and chronic scarring or irreversible damage.\n3. **To guide treatment decisions:** When the initial biopsy class is known but the clinical presentation changes significantly, to assess for class transformation or mixed classes.\n4. **Persistent proteinuria or renal abnormalities despite treatment:** To evaluate ongoing disease activity versus damage.\n5. **Assessment before changing or stopping immunosuppressive therapy:** To confirm disease inactivity.\n\nRepeat biopsy helps tailor therapy by providing updated histological information."
    },
    {
        "pregunta": "17. What are the treatment recommendations for patients with pure class V lupus nephritis with proteinuria ≥1 g/g?",
        "respuesta": "For patients with pure class V lupus nephritis (membranous lupus nephritis) and proteinuria ≥1 g/g, treatment typically includes:\n\n1. **Immunosuppressive therapy**: \n   - First-line treatment often involves **mycophenolate mofetil (MMF)** or **cyclophosphamide** combined with corticosteroids.\n2. **Corticosteroids**: \n   - Moderate-dose corticosteroids are used to control inflammation.\n3. **Adjunctive therapy**: \n   - Use of **renin-angiotensin system (RAS) blockers** (ACE inhibitors or ARBs) to reduce proteinuria and protect kidney function.\n4. **Supportive care**: \n   - Blood pressure control, lipid management, and monitoring for disease activity.\n\nTreatment should be individualized based on patient factors and disease severity, and close monitoring is essential."
    },
    {
        "pregunta": "18. How often should proteinuria be quantified in patients with lupus nephritis who have not achieved complete renal response?",
        "respuesta": "In patients with lupus nephritis who have not achieved complete renal response, proteinuria should generally be quantified at least every 1 to 3 months to closely monitor disease activity and guide treatment adjustments."
    },
    {
        "pregunta": "19. What are the recommendations regarding anticoagulation therapy in lupus nephritis patients with thrombosis risk factors?",
        "respuesta": "In lupus nephritis patients with thrombosis risk factors, anticoagulation therapy is generally recommended if there is a history of thrombotic events or presence of antiphospholipid antibodies (especially lupus anticoagulant, anticardiolipin, or anti-β2 glycoprotein I antibodies) indicating antiphospholipid syndrome (APS). Long-term anticoagulation with warfarin aiming for an INR of 2.0–3.0 is typically advised to prevent recurrent thrombosis. In patients without prior thrombosis but with high-risk antiphospholipid antibody profiles, low-dose aspirin may be considered. The decision should be individualized based on bleeding risk, presence of active nephritis, and other clinical factors."
    },
    {
        "pregunta": "20. What is the recommended duration of immunosuppressive therapy for patients achieving complete renal response in lupus nephritis?",
        "respuesta": "The recommended duration of immunosuppressive therapy for patients achieving complete renal response in lupus nephritis is generally at least 3 to 5 years. This typically includes an initial induction phase followed by a maintenance phase to prevent relapse. After achieving complete renal response, maintenance immunosuppression is usually continued for a minimum of 3 years before considering gradual tapering, depending on individual patient factors and risk of relapse."
    }
]